Skip to main content
Skip to navigation
Research Exchange
Living Lab
Discovery Lab
Donate
Senaparib: First Approval
Arnold Lee
· 2025-07-30
Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated benefits in progression-free survival for first-line maintenance therapy of ovarian cancer. Senaparib (
Links
DOI
PubMed
Journal
Drugs
Institutions
Springer Nature New Zealand
Authors
Arnold Lee